nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—SLC31A1—Carboplatin—urinary bladder cancer	0.225	0.44	CbGbCtD
Bortezomib—SLC31A1—Cisplatin—urinary bladder cancer	0.192	0.376	CbGbCtD
Bortezomib—PTGS1—Etoposide—urinary bladder cancer	0.0165	0.0324	CbGbCtD
Bortezomib—CYP3A4—Thiotepa—urinary bladder cancer	0.0143	0.0279	CbGbCtD
Bortezomib—CYP2C8—Fluorouracil—urinary bladder cancer	0.0114	0.0224	CbGbCtD
Bortezomib—CYP2C8—Etoposide—urinary bladder cancer	0.00954	0.0187	CbGbCtD
Bortezomib—CYP1A2—Fluorouracil—urinary bladder cancer	0.00885	0.0173	CbGbCtD
Bortezomib—CYP2C9—Fluorouracil—urinary bladder cancer	0.00797	0.0156	CbGbCtD
Bortezomib—CYP1A2—Etoposide—urinary bladder cancer	0.00739	0.0145	CbGbCtD
Bortezomib—CYP2C9—Cisplatin—urinary bladder cancer	0.00677	0.0133	CbGbCtD
Bortezomib—CYP2D6—Doxorubicin—urinary bladder cancer	0.00415	0.00813	CbGbCtD
Bortezomib—CYP3A4—Etoposide—urinary bladder cancer	0.00387	0.00758	CbGbCtD
Bortezomib—CTSG—prostate gland—urinary bladder cancer	0.00344	0.0329	CbGeAlD
Bortezomib—PSMA1—prostate gland—urinary bladder cancer	0.0033	0.0316	CbGeAlD
Bortezomib—Aspartame—TRPV1—urinary bladder cancer	0.00304	0.831	CrCbGaD
Bortezomib—CTSG—seminal vesicle—urinary bladder cancer	0.00291	0.0278	CbGeAlD
Bortezomib—PSMD1—prostate gland—urinary bladder cancer	0.00277	0.0265	CbGeAlD
Bortezomib—CYP3A4—Doxorubicin—urinary bladder cancer	0.00264	0.00517	CbGbCtD
Bortezomib—PSMD2—prostate gland—urinary bladder cancer	0.00246	0.0235	CbGeAlD
Bortezomib—PSMB8—prostate gland—urinary bladder cancer	0.00244	0.0234	CbGeAlD
Bortezomib—PSMA1—epithelium—urinary bladder cancer	0.00243	0.0232	CbGeAlD
Bortezomib—PSMD1—seminal vesicle—urinary bladder cancer	0.00235	0.0224	CbGeAlD
Bortezomib—CTSG—urethra—urinary bladder cancer	0.0023	0.022	CbGeAlD
Bortezomib—PSMA1—renal system—urinary bladder cancer	0.00225	0.0215	CbGeAlD
Bortezomib—PSMB5—prostate gland—urinary bladder cancer	0.00216	0.0206	CbGeAlD
Bortezomib—PSMD2—seminal vesicle—urinary bladder cancer	0.00208	0.0199	CbGeAlD
Bortezomib—PSMB8—seminal vesicle—urinary bladder cancer	0.00207	0.0198	CbGeAlD
Bortezomib—PSMD1—smooth muscle tissue—urinary bladder cancer	0.00196	0.0188	CbGeAlD
Bortezomib—PSMB1—prostate gland—urinary bladder cancer	0.00189	0.018	CbGeAlD
Bortezomib—CYP2C19—urine—urinary bladder cancer	0.00187	0.0179	CbGeAlD
Bortezomib—PSMD1—urethra—urinary bladder cancer	0.00186	0.0178	CbGeAlD
Bortezomib—PSMB2—prostate gland—urinary bladder cancer	0.00184	0.0176	CbGeAlD
Bortezomib—PSMB5—seminal vesicle—urinary bladder cancer	0.00182	0.0175	CbGeAlD
Bortezomib—PSMA1—female reproductive system—urinary bladder cancer	0.0018	0.0173	CbGeAlD
Bortezomib—PSMD2—smooth muscle tissue—urinary bladder cancer	0.00174	0.0166	CbGeAlD
Bortezomib—CTSG—vagina—urinary bladder cancer	0.0017	0.0163	CbGeAlD
Bortezomib—PSMD2—renal system—urinary bladder cancer	0.00168	0.016	CbGeAlD
Bortezomib—PSMD2—urethra—urinary bladder cancer	0.00165	0.0157	CbGeAlD
Bortezomib—PSMB8—urethra—urinary bladder cancer	0.00164	0.0156	CbGeAlD
Bortezomib—PSMB1—seminal vesicle—urinary bladder cancer	0.0016	0.0153	CbGeAlD
Bortezomib—SLC31A1—prostate gland—urinary bladder cancer	0.00159	0.0152	CbGeAlD
Bortezomib—PSMB2—seminal vesicle—urinary bladder cancer	0.00156	0.0149	CbGeAlD
Bortezomib—CYP1A2—urine—urinary bladder cancer	0.00153	0.0146	CbGeAlD
Bortezomib—PSMB5—smooth muscle tissue—urinary bladder cancer	0.00153	0.0146	CbGeAlD
Bortezomib—PSMB2—Azacitidine—Gemcitabine—urinary bladder cancer	0.00146	0.529	CbGdCrCtD
Bortezomib—CYP2C9—urine—urinary bladder cancer	0.00145	0.0139	CbGeAlD
Bortezomib—PSMB5—urethra—urinary bladder cancer	0.00144	0.0138	CbGeAlD
Bortezomib—PSMD1—vagina—urinary bladder cancer	0.00137	0.0131	CbGeAlD
Bortezomib—SLC31A1—seminal vesicle—urinary bladder cancer	0.00135	0.0129	CbGeAlD
Bortezomib—PSMD2—female reproductive system—urinary bladder cancer	0.00134	0.0128	CbGeAlD
Bortezomib—PSMB1—smooth muscle tissue—urinary bladder cancer	0.00134	0.0128	CbGeAlD
Bortezomib—PSMB2—smooth muscle tissue—urinary bladder cancer	0.0013	0.0125	CbGeAlD
Bortezomib—PSMB8—Podofilox—Etoposide—urinary bladder cancer	0.0013	0.47	CbGdCrCtD
Bortezomib—PSMB1—renal system—urinary bladder cancer	0.00129	0.0123	CbGeAlD
Bortezomib—PSMB1—urethra—urinary bladder cancer	0.00126	0.0121	CbGeAlD
Bortezomib—PSMB2—renal system—urinary bladder cancer	0.00125	0.012	CbGeAlD
Bortezomib—PSMB2—urethra—urinary bladder cancer	0.00123	0.0118	CbGeAlD
Bortezomib—PSMD2—vagina—urinary bladder cancer	0.00121	0.0116	CbGeAlD
Bortezomib—PSMB8—vagina—urinary bladder cancer	0.00121	0.0115	CbGeAlD
Bortezomib—CYP3A4—urine—urinary bladder cancer	0.00111	0.0106	CbGeAlD
Bortezomib—CTSG—lymph node—urinary bladder cancer	0.0011	0.0105	CbGeAlD
Bortezomib—CYP2D6—urine—urinary bladder cancer	0.00109	0.0104	CbGeAlD
Bortezomib—SLC31A1—renal system—urinary bladder cancer	0.00109	0.0104	CbGeAlD
Bortezomib—SLC31A1—urethra—urinary bladder cancer	0.00107	0.0102	CbGeAlD
Bortezomib—PSMB5—vagina—urinary bladder cancer	0.00107	0.0102	CbGeAlD
Bortezomib—PSMA1—lymph node—urinary bladder cancer	0.00106	0.0101	CbGeAlD
Bortezomib—PSMB1—female reproductive system—urinary bladder cancer	0.00103	0.00985	CbGeAlD
Bortezomib—PSMB2—female reproductive system—urinary bladder cancer	0.001	0.00961	CbGeAlD
Bortezomib—PSMB1—vagina—urinary bladder cancer	0.000931	0.0089	CbGeAlD
Bortezomib—PSMB2—vagina—urinary bladder cancer	0.000908	0.00869	CbGeAlD
Bortezomib—PSMD1—lymph node—urinary bladder cancer	0.000886	0.00847	CbGeAlD
Bortezomib—SLC31A1—female reproductive system—urinary bladder cancer	0.00087	0.00832	CbGeAlD
Bortezomib—SLC31A1—vagina—urinary bladder cancer	0.000787	0.00752	CbGeAlD
Bortezomib—PSMD2—lymph node—urinary bladder cancer	0.000785	0.00751	CbGeAlD
Bortezomib—PSMB8—lymph node—urinary bladder cancer	0.00078	0.00746	CbGeAlD
Bortezomib—PSMB5—lymph node—urinary bladder cancer	0.000689	0.00659	CbGeAlD
Bortezomib—Nateglinide—PPARG—urinary bladder cancer	0.00062	0.169	CrCbGaD
Bortezomib—PSMB1—lymph node—urinary bladder cancer	0.000602	0.00576	CbGeAlD
Bortezomib—PSMB2—lymph node—urinary bladder cancer	0.000588	0.00562	CbGeAlD
Bortezomib—SLC31A1—lymph node—urinary bladder cancer	0.000509	0.00487	CbGeAlD
Bortezomib—PTGS1—prostate gland—urinary bladder cancer	0.000475	0.00455	CbGeAlD
Bortezomib—PTGS1—seminal vesicle—urinary bladder cancer	0.000402	0.00385	CbGeAlD
Bortezomib—CYP2C8—renal system—urinary bladder cancer	0.0004	0.00382	CbGeAlD
Bortezomib—CYP1A1—epithelium—urinary bladder cancer	0.000398	0.0038	CbGeAlD
Bortezomib—CYP1A2—renal system—urinary bladder cancer	0.000374	0.00358	CbGeAlD
Bortezomib—CYP1A1—renal system—urinary bladder cancer	0.000369	0.00353	CbGeAlD
Bortezomib—CYP1A1—urethra—urinary bladder cancer	0.000362	0.00347	CbGeAlD
Bortezomib—PTGS1—epithelium—urinary bladder cancer	0.000349	0.00334	CbGeAlD
Bortezomib—PTGS1—smooth muscle tissue—urinary bladder cancer	0.000337	0.00322	CbGeAlD
Bortezomib—CYP2C19—vagina—urinary bladder cancer	0.000332	0.00317	CbGeAlD
Bortezomib—PTGS1—renal system—urinary bladder cancer	0.000324	0.0031	CbGeAlD
Bortezomib—CYP2C8—female reproductive system—urinary bladder cancer	0.00032	0.00306	CbGeAlD
Bortezomib—CYP1A1—female reproductive system—urinary bladder cancer	0.000295	0.00283	CbGeAlD
Bortezomib—CYP2C8—vagina—urinary bladder cancer	0.000289	0.00277	CbGeAlD
Bortezomib—CYP2C9—female reproductive system—urinary bladder cancer	0.000284	0.00272	CbGeAlD
Bortezomib—CYP3A4—renal system—urinary bladder cancer	0.000271	0.00259	CbGeAlD
Bortezomib—CYP1A1—vagina—urinary bladder cancer	0.000267	0.00256	CbGeAlD
Bortezomib—CYP2D6—renal system—urinary bladder cancer	0.000266	0.00255	CbGeAlD
Bortezomib—PTGS1—female reproductive system—urinary bladder cancer	0.00026	0.00248	CbGeAlD
Bortezomib—PTGS1—vagina—urinary bladder cancer	0.000235	0.00224	CbGeAlD
Bortezomib—CYP3A4—female reproductive system—urinary bladder cancer	0.000217	0.00207	CbGeAlD
Bortezomib—CYP2D6—female reproductive system—urinary bladder cancer	0.000213	0.00204	CbGeAlD
Bortezomib—CYP1A1—lymph node—urinary bladder cancer	0.000173	0.00165	CbGeAlD
Bortezomib—PTGS1—lymph node—urinary bladder cancer	0.000152	0.00145	CbGeAlD
Bortezomib—Tinnitus—Methotrexate—urinary bladder cancer	4.16e-05	0.000202	CcSEcCtD
Bortezomib—Hypoaesthesia—Epirubicin—urinary bladder cancer	4.16e-05	0.000202	CcSEcCtD
Bortezomib—Asthenia—Cisplatin—urinary bladder cancer	4.15e-05	0.000201	CcSEcCtD
Bortezomib—Cardiac disorder—Methotrexate—urinary bladder cancer	4.14e-05	0.000201	CcSEcCtD
Bortezomib—Urinary tract disorder—Epirubicin—urinary bladder cancer	4.12e-05	0.0002	CcSEcCtD
Bortezomib—Oedema peripheral—Epirubicin—urinary bladder cancer	4.11e-05	0.0002	CcSEcCtD
Bortezomib—Haematuria—Doxorubicin—urinary bladder cancer	4.1e-05	0.000199	CcSEcCtD
Bortezomib—Connective tissue disorder—Epirubicin—urinary bladder cancer	4.1e-05	0.000199	CcSEcCtD
Bortezomib—Urethral disorder—Epirubicin—urinary bladder cancer	4.09e-05	0.000199	CcSEcCtD
Bortezomib—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	4.07e-05	0.000198	CcSEcCtD
Bortezomib—Epistaxis—Doxorubicin—urinary bladder cancer	4.06e-05	0.000197	CcSEcCtD
Bortezomib—Angiopathy—Methotrexate—urinary bladder cancer	4.05e-05	0.000197	CcSEcCtD
Bortezomib—Sinusitis—Doxorubicin—urinary bladder cancer	4.04e-05	0.000196	CcSEcCtD
Bortezomib—Immune system disorder—Methotrexate—urinary bladder cancer	4.03e-05	0.000196	CcSEcCtD
Bortezomib—Dizziness—Fluorouracil—urinary bladder cancer	4.03e-05	0.000196	CcSEcCtD
Bortezomib—Visual impairment—Epirubicin—urinary bladder cancer	4.02e-05	0.000196	CcSEcCtD
Bortezomib—Mediastinal disorder—Methotrexate—urinary bladder cancer	4.02e-05	0.000195	CcSEcCtD
Bortezomib—Chills—Methotrexate—urinary bladder cancer	4e-05	0.000195	CcSEcCtD
Bortezomib—Diarrhoea—Cisplatin—urinary bladder cancer	3.95e-05	0.000192	CcSEcCtD
Bortezomib—Erythema multiforme—Epirubicin—urinary bladder cancer	3.95e-05	0.000192	CcSEcCtD
Bortezomib—Vomiting—Gemcitabine—urinary bladder cancer	3.94e-05	0.000191	CcSEcCtD
Bortezomib—Bradycardia—Doxorubicin—urinary bladder cancer	3.93e-05	0.000191	CcSEcCtD
Bortezomib—Mental disorder—Methotrexate—urinary bladder cancer	3.91e-05	0.00019	CcSEcCtD
Bortezomib—Rash—Gemcitabine—urinary bladder cancer	3.91e-05	0.00019	CcSEcCtD
Bortezomib—Dermatitis—Gemcitabine—urinary bladder cancer	3.9e-05	0.00019	CcSEcCtD
Bortezomib—Eye disorder—Epirubicin—urinary bladder cancer	3.9e-05	0.00019	CcSEcCtD
Bortezomib—Hypersensitivity—Etoposide—urinary bladder cancer	3.9e-05	0.000189	CcSEcCtD
Bortezomib—Tinnitus—Epirubicin—urinary bladder cancer	3.89e-05	0.000189	CcSEcCtD
Bortezomib—Malnutrition—Methotrexate—urinary bladder cancer	3.88e-05	0.000189	CcSEcCtD
Bortezomib—Erythema—Methotrexate—urinary bladder cancer	3.88e-05	0.000189	CcSEcCtD
Bortezomib—Haemoglobin—Doxorubicin—urinary bladder cancer	3.88e-05	0.000189	CcSEcCtD
Bortezomib—Headache—Gemcitabine—urinary bladder cancer	3.88e-05	0.000189	CcSEcCtD
Bortezomib—Cardiac disorder—Epirubicin—urinary bladder cancer	3.88e-05	0.000188	CcSEcCtD
Bortezomib—Flushing—Epirubicin—urinary bladder cancer	3.88e-05	0.000188	CcSEcCtD
Bortezomib—Vomiting—Fluorouracil—urinary bladder cancer	3.88e-05	0.000188	CcSEcCtD
Bortezomib—Haemorrhage—Doxorubicin—urinary bladder cancer	3.86e-05	0.000188	CcSEcCtD
Bortezomib—Hepatitis—Doxorubicin—urinary bladder cancer	3.86e-05	0.000188	CcSEcCtD
Bortezomib—Hypoaesthesia—Doxorubicin—urinary bladder cancer	3.85e-05	0.000187	CcSEcCtD
Bortezomib—Rash—Fluorouracil—urinary bladder cancer	3.84e-05	0.000187	CcSEcCtD
Bortezomib—Dermatitis—Fluorouracil—urinary bladder cancer	3.84e-05	0.000187	CcSEcCtD
Bortezomib—Headache—Fluorouracil—urinary bladder cancer	3.82e-05	0.000185	CcSEcCtD
Bortezomib—Urinary tract disorder—Doxorubicin—urinary bladder cancer	3.82e-05	0.000185	CcSEcCtD
Bortezomib—Oedema peripheral—Doxorubicin—urinary bladder cancer	3.81e-05	0.000185	CcSEcCtD
Bortezomib—Dysgeusia—Methotrexate—urinary bladder cancer	3.8e-05	0.000185	CcSEcCtD
Bortezomib—Asthenia—Etoposide—urinary bladder cancer	3.8e-05	0.000185	CcSEcCtD
Bortezomib—Connective tissue disorder—Doxorubicin—urinary bladder cancer	3.8e-05	0.000184	CcSEcCtD
Bortezomib—Angiopathy—Epirubicin—urinary bladder cancer	3.79e-05	0.000184	CcSEcCtD
Bortezomib—Urethral disorder—Doxorubicin—urinary bladder cancer	3.79e-05	0.000184	CcSEcCtD
Bortezomib—Immune system disorder—Epirubicin—urinary bladder cancer	3.77e-05	0.000183	CcSEcCtD
Bortezomib—Mediastinal disorder—Epirubicin—urinary bladder cancer	3.76e-05	0.000183	CcSEcCtD
Bortezomib—Back pain—Methotrexate—urinary bladder cancer	3.76e-05	0.000183	CcSEcCtD
Bortezomib—Chills—Epirubicin—urinary bladder cancer	3.75e-05	0.000182	CcSEcCtD
Bortezomib—Pruritus—Etoposide—urinary bladder cancer	3.75e-05	0.000182	CcSEcCtD
Bortezomib—Arrhythmia—Epirubicin—urinary bladder cancer	3.73e-05	0.000181	CcSEcCtD
Bortezomib—Visual impairment—Doxorubicin—urinary bladder cancer	3.72e-05	0.000181	CcSEcCtD
Bortezomib—Nausea—Gemcitabine—urinary bladder cancer	3.68e-05	0.000179	CcSEcCtD
Bortezomib—Vomiting—Cisplatin—urinary bladder cancer	3.67e-05	0.000178	CcSEcCtD
Bortezomib—Vision blurred—Methotrexate—urinary bladder cancer	3.66e-05	0.000178	CcSEcCtD
Bortezomib—Mental disorder—Epirubicin—urinary bladder cancer	3.66e-05	0.000178	CcSEcCtD
Bortezomib—Erythema multiforme—Doxorubicin—urinary bladder cancer	3.65e-05	0.000178	CcSEcCtD
Bortezomib—Rash—Cisplatin—urinary bladder cancer	3.64e-05	0.000177	CcSEcCtD
Bortezomib—Dermatitis—Cisplatin—urinary bladder cancer	3.64e-05	0.000177	CcSEcCtD
Bortezomib—Erythema—Epirubicin—urinary bladder cancer	3.64e-05	0.000177	CcSEcCtD
Bortezomib—Malnutrition—Epirubicin—urinary bladder cancer	3.64e-05	0.000177	CcSEcCtD
Bortezomib—Diarrhoea—Etoposide—urinary bladder cancer	3.62e-05	0.000176	CcSEcCtD
Bortezomib—Nausea—Fluorouracil—urinary bladder cancer	3.62e-05	0.000176	CcSEcCtD
Bortezomib—Eye disorder—Doxorubicin—urinary bladder cancer	3.61e-05	0.000175	CcSEcCtD
Bortezomib—Ill-defined disorder—Methotrexate—urinary bladder cancer	3.6e-05	0.000175	CcSEcCtD
Bortezomib—Tinnitus—Doxorubicin—urinary bladder cancer	3.6e-05	0.000175	CcSEcCtD
Bortezomib—Anaemia—Methotrexate—urinary bladder cancer	3.59e-05	0.000174	CcSEcCtD
Bortezomib—Cardiac disorder—Doxorubicin—urinary bladder cancer	3.59e-05	0.000174	CcSEcCtD
Bortezomib—Flushing—Doxorubicin—urinary bladder cancer	3.59e-05	0.000174	CcSEcCtD
Bortezomib—Flatulence—Epirubicin—urinary bladder cancer	3.58e-05	0.000174	CcSEcCtD
Bortezomib—Dysgeusia—Epirubicin—urinary bladder cancer	3.56e-05	0.000173	CcSEcCtD
Bortezomib—Back pain—Epirubicin—urinary bladder cancer	3.52e-05	0.000171	CcSEcCtD
Bortezomib—Angiopathy—Doxorubicin—urinary bladder cancer	3.51e-05	0.00017	CcSEcCtD
Bortezomib—Malaise—Methotrexate—urinary bladder cancer	3.5e-05	0.00017	CcSEcCtD
Bortezomib—Dizziness—Etoposide—urinary bladder cancer	3.5e-05	0.00017	CcSEcCtD
Bortezomib—Muscle spasms—Epirubicin—urinary bladder cancer	3.5e-05	0.00017	CcSEcCtD
Bortezomib—Immune system disorder—Doxorubicin—urinary bladder cancer	3.49e-05	0.00017	CcSEcCtD
Bortezomib—Vertigo—Methotrexate—urinary bladder cancer	3.49e-05	0.00017	CcSEcCtD
Bortezomib—Mediastinal disorder—Doxorubicin—urinary bladder cancer	3.48e-05	0.000169	CcSEcCtD
Bortezomib—Leukopenia—Methotrexate—urinary bladder cancer	3.48e-05	0.000169	CcSEcCtD
Bortezomib—Chills—Doxorubicin—urinary bladder cancer	3.47e-05	0.000168	CcSEcCtD
Bortezomib—Arrhythmia—Doxorubicin—urinary bladder cancer	3.45e-05	0.000168	CcSEcCtD
Bortezomib—Nausea—Cisplatin—urinary bladder cancer	3.43e-05	0.000167	CcSEcCtD
Bortezomib—Vision blurred—Epirubicin—urinary bladder cancer	3.43e-05	0.000166	CcSEcCtD
Bortezomib—Cough—Methotrexate—urinary bladder cancer	3.39e-05	0.000165	CcSEcCtD
Bortezomib—Mental disorder—Doxorubicin—urinary bladder cancer	3.39e-05	0.000164	CcSEcCtD
Bortezomib—Ill-defined disorder—Epirubicin—urinary bladder cancer	3.37e-05	0.000164	CcSEcCtD
Bortezomib—Convulsion—Methotrexate—urinary bladder cancer	3.37e-05	0.000164	CcSEcCtD
Bortezomib—Vomiting—Etoposide—urinary bladder cancer	3.37e-05	0.000164	CcSEcCtD
Bortezomib—Erythema—Doxorubicin—urinary bladder cancer	3.36e-05	0.000163	CcSEcCtD
Bortezomib—Malnutrition—Doxorubicin—urinary bladder cancer	3.36e-05	0.000163	CcSEcCtD
Bortezomib—Anaemia—Epirubicin—urinary bladder cancer	3.36e-05	0.000163	CcSEcCtD
Bortezomib—Agitation—Epirubicin—urinary bladder cancer	3.34e-05	0.000162	CcSEcCtD
Bortezomib—Rash—Etoposide—urinary bladder cancer	3.34e-05	0.000162	CcSEcCtD
Bortezomib—Dermatitis—Etoposide—urinary bladder cancer	3.33e-05	0.000162	CcSEcCtD
Bortezomib—Headache—Etoposide—urinary bladder cancer	3.32e-05	0.000161	CcSEcCtD
Bortezomib—Flatulence—Doxorubicin—urinary bladder cancer	3.31e-05	0.000161	CcSEcCtD
Bortezomib—Chest pain—Methotrexate—urinary bladder cancer	3.31e-05	0.000161	CcSEcCtD
Bortezomib—Myalgia—Methotrexate—urinary bladder cancer	3.31e-05	0.000161	CcSEcCtD
Bortezomib—Arthralgia—Methotrexate—urinary bladder cancer	3.31e-05	0.000161	CcSEcCtD
Bortezomib—Dysgeusia—Doxorubicin—urinary bladder cancer	3.29e-05	0.00016	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	3.28e-05	0.00016	CcSEcCtD
Bortezomib—Malaise—Epirubicin—urinary bladder cancer	3.28e-05	0.000159	CcSEcCtD
Bortezomib—Discomfort—Methotrexate—urinary bladder cancer	3.27e-05	0.000159	CcSEcCtD
Bortezomib—Vertigo—Epirubicin—urinary bladder cancer	3.27e-05	0.000159	CcSEcCtD
Bortezomib—Syncope—Epirubicin—urinary bladder cancer	3.26e-05	0.000158	CcSEcCtD
Bortezomib—Leukopenia—Epirubicin—urinary bladder cancer	3.25e-05	0.000158	CcSEcCtD
Bortezomib—Back pain—Doxorubicin—urinary bladder cancer	3.25e-05	0.000158	CcSEcCtD
Bortezomib—Muscle spasms—Doxorubicin—urinary bladder cancer	3.23e-05	0.000157	CcSEcCtD
Bortezomib—Palpitations—Epirubicin—urinary bladder cancer	3.21e-05	0.000156	CcSEcCtD
Bortezomib—Confusional state—Methotrexate—urinary bladder cancer	3.2e-05	0.000155	CcSEcCtD
Bortezomib—Loss of consciousness—Epirubicin—urinary bladder cancer	3.2e-05	0.000155	CcSEcCtD
Bortezomib—Cough—Epirubicin—urinary bladder cancer	3.17e-05	0.000154	CcSEcCtD
Bortezomib—Anaphylactic shock—Methotrexate—urinary bladder cancer	3.17e-05	0.000154	CcSEcCtD
Bortezomib—Vision blurred—Doxorubicin—urinary bladder cancer	3.17e-05	0.000154	CcSEcCtD
Bortezomib—Convulsion—Epirubicin—urinary bladder cancer	3.15e-05	0.000153	CcSEcCtD
Bortezomib—Infection—Methotrexate—urinary bladder cancer	3.15e-05	0.000153	CcSEcCtD
Bortezomib—Nausea—Etoposide—urinary bladder cancer	3.14e-05	0.000153	CcSEcCtD
Bortezomib—Hypertension—Epirubicin—urinary bladder cancer	3.14e-05	0.000152	CcSEcCtD
Bortezomib—Ill-defined disorder—Doxorubicin—urinary bladder cancer	3.12e-05	0.000152	CcSEcCtD
Bortezomib—Nervous system disorder—Methotrexate—urinary bladder cancer	3.11e-05	0.000151	CcSEcCtD
Bortezomib—Anaemia—Doxorubicin—urinary bladder cancer	3.11e-05	0.000151	CcSEcCtD
Bortezomib—Thrombocytopenia—Methotrexate—urinary bladder cancer	3.1e-05	0.000151	CcSEcCtD
Bortezomib—Myalgia—Epirubicin—urinary bladder cancer	3.1e-05	0.00015	CcSEcCtD
Bortezomib—Chest pain—Epirubicin—urinary bladder cancer	3.1e-05	0.00015	CcSEcCtD
Bortezomib—Arthralgia—Epirubicin—urinary bladder cancer	3.1e-05	0.00015	CcSEcCtD
Bortezomib—Agitation—Doxorubicin—urinary bladder cancer	3.09e-05	0.00015	CcSEcCtD
Bortezomib—Anxiety—Epirubicin—urinary bladder cancer	3.08e-05	0.00015	CcSEcCtD
Bortezomib—Skin disorder—Methotrexate—urinary bladder cancer	3.08e-05	0.00015	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	3.07e-05	0.000149	CcSEcCtD
Bortezomib—Hyperhidrosis—Methotrexate—urinary bladder cancer	3.07e-05	0.000149	CcSEcCtD
Bortezomib—Discomfort—Epirubicin—urinary bladder cancer	3.06e-05	0.000149	CcSEcCtD
Bortezomib—Malaise—Doxorubicin—urinary bladder cancer	3.03e-05	0.000147	CcSEcCtD
Bortezomib—Vertigo—Doxorubicin—urinary bladder cancer	3.02e-05	0.000147	CcSEcCtD
Bortezomib—Anorexia—Methotrexate—urinary bladder cancer	3.02e-05	0.000147	CcSEcCtD
Bortezomib—Syncope—Doxorubicin—urinary bladder cancer	3.02e-05	0.000147	CcSEcCtD
Bortezomib—Leukopenia—Doxorubicin—urinary bladder cancer	3.01e-05	0.000146	CcSEcCtD
Bortezomib—Confusional state—Epirubicin—urinary bladder cancer	2.99e-05	0.000145	CcSEcCtD
Bortezomib—Palpitations—Doxorubicin—urinary bladder cancer	2.97e-05	0.000144	CcSEcCtD
Bortezomib—Oedema—Epirubicin—urinary bladder cancer	2.97e-05	0.000144	CcSEcCtD
Bortezomib—Anaphylactic shock—Epirubicin—urinary bladder cancer	2.97e-05	0.000144	CcSEcCtD
Bortezomib—Hypotension—Methotrexate—urinary bladder cancer	2.96e-05	0.000144	CcSEcCtD
Bortezomib—Loss of consciousness—Doxorubicin—urinary bladder cancer	2.96e-05	0.000144	CcSEcCtD
Bortezomib—Infection—Epirubicin—urinary bladder cancer	2.95e-05	0.000143	CcSEcCtD
Bortezomib—Cough—Doxorubicin—urinary bladder cancer	2.94e-05	0.000143	CcSEcCtD
Bortezomib—Shock—Epirubicin—urinary bladder cancer	2.92e-05	0.000142	CcSEcCtD
Bortezomib—Convulsion—Doxorubicin—urinary bladder cancer	2.91e-05	0.000142	CcSEcCtD
Bortezomib—Nervous system disorder—Epirubicin—urinary bladder cancer	2.91e-05	0.000141	CcSEcCtD
Bortezomib—Thrombocytopenia—Epirubicin—urinary bladder cancer	2.91e-05	0.000141	CcSEcCtD
Bortezomib—Hypertension—Doxorubicin—urinary bladder cancer	2.9e-05	0.000141	CcSEcCtD
Bortezomib—Tachycardia—Epirubicin—urinary bladder cancer	2.9e-05	0.000141	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	2.89e-05	0.00014	CcSEcCtD
Bortezomib—Skin disorder—Epirubicin—urinary bladder cancer	2.88e-05	0.00014	CcSEcCtD
Bortezomib—Hyperhidrosis—Epirubicin—urinary bladder cancer	2.87e-05	0.000139	CcSEcCtD
Bortezomib—Insomnia—Methotrexate—urinary bladder cancer	2.87e-05	0.000139	CcSEcCtD
Bortezomib—Chest pain—Doxorubicin—urinary bladder cancer	2.86e-05	0.000139	CcSEcCtD
Bortezomib—Myalgia—Doxorubicin—urinary bladder cancer	2.86e-05	0.000139	CcSEcCtD
Bortezomib—Arthralgia—Doxorubicin—urinary bladder cancer	2.86e-05	0.000139	CcSEcCtD
Bortezomib—Anxiety—Doxorubicin—urinary bladder cancer	2.85e-05	0.000139	CcSEcCtD
Bortezomib—Paraesthesia—Methotrexate—urinary bladder cancer	2.85e-05	0.000138	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	2.84e-05	0.000138	CcSEcCtD
Bortezomib—Discomfort—Doxorubicin—urinary bladder cancer	2.83e-05	0.000137	CcSEcCtD
Bortezomib—Anorexia—Epirubicin—urinary bladder cancer	2.83e-05	0.000137	CcSEcCtD
Bortezomib—Dyspnoea—Methotrexate—urinary bladder cancer	2.83e-05	0.000137	CcSEcCtD
Bortezomib—Dyspepsia—Methotrexate—urinary bladder cancer	2.79e-05	0.000136	CcSEcCtD
Bortezomib—Hypotension—Epirubicin—urinary bladder cancer	2.77e-05	0.000135	CcSEcCtD
Bortezomib—Confusional state—Doxorubicin—urinary bladder cancer	2.77e-05	0.000134	CcSEcCtD
Bortezomib—Decreased appetite—Methotrexate—urinary bladder cancer	2.76e-05	0.000134	CcSEcCtD
Bortezomib—Oedema—Doxorubicin—urinary bladder cancer	2.75e-05	0.000133	CcSEcCtD
Bortezomib—Anaphylactic shock—Doxorubicin—urinary bladder cancer	2.75e-05	0.000133	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	2.74e-05	0.000133	CcSEcCtD
Bortezomib—Fatigue—Methotrexate—urinary bladder cancer	2.73e-05	0.000133	CcSEcCtD
Bortezomib—Infection—Doxorubicin—urinary bladder cancer	2.73e-05	0.000133	CcSEcCtD
Bortezomib—Pain—Methotrexate—urinary bladder cancer	2.71e-05	0.000132	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	2.7e-05	0.000131	CcSEcCtD
Bortezomib—Shock—Doxorubicin—urinary bladder cancer	2.7e-05	0.000131	CcSEcCtD
Bortezomib—Nervous system disorder—Doxorubicin—urinary bladder cancer	2.69e-05	0.000131	CcSEcCtD
Bortezomib—Thrombocytopenia—Doxorubicin—urinary bladder cancer	2.69e-05	0.000131	CcSEcCtD
Bortezomib—Insomnia—Epirubicin—urinary bladder cancer	2.68e-05	0.00013	CcSEcCtD
Bortezomib—Tachycardia—Doxorubicin—urinary bladder cancer	2.68e-05	0.00013	CcSEcCtD
Bortezomib—Skin disorder—Doxorubicin—urinary bladder cancer	2.67e-05	0.00013	CcSEcCtD
Bortezomib—Paraesthesia—Epirubicin—urinary bladder cancer	2.66e-05	0.000129	CcSEcCtD
Bortezomib—Hyperhidrosis—Doxorubicin—urinary bladder cancer	2.65e-05	0.000129	CcSEcCtD
Bortezomib—Dyspnoea—Epirubicin—urinary bladder cancer	2.65e-05	0.000129	CcSEcCtD
Bortezomib—Anorexia—Doxorubicin—urinary bladder cancer	2.62e-05	0.000127	CcSEcCtD
Bortezomib—Feeling abnormal—Methotrexate—urinary bladder cancer	2.61e-05	0.000127	CcSEcCtD
Bortezomib—Dyspepsia—Epirubicin—urinary bladder cancer	2.61e-05	0.000127	CcSEcCtD
Bortezomib—Gastrointestinal pain—Methotrexate—urinary bladder cancer	2.59e-05	0.000126	CcSEcCtD
Bortezomib—Decreased appetite—Epirubicin—urinary bladder cancer	2.58e-05	0.000125	CcSEcCtD
Bortezomib—Hypotension—Doxorubicin—urinary bladder cancer	2.57e-05	0.000125	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	2.56e-05	0.000124	CcSEcCtD
Bortezomib—Fatigue—Epirubicin—urinary bladder cancer	2.56e-05	0.000124	CcSEcCtD
Bortezomib—Constipation—Epirubicin—urinary bladder cancer	2.54e-05	0.000123	CcSEcCtD
Bortezomib—Pain—Epirubicin—urinary bladder cancer	2.54e-05	0.000123	CcSEcCtD
Bortezomib—Urticaria—Methotrexate—urinary bladder cancer	2.52e-05	0.000122	CcSEcCtD
Bortezomib—Abdominal pain—Methotrexate—urinary bladder cancer	2.51e-05	0.000122	CcSEcCtD
Bortezomib—Body temperature increased—Methotrexate—urinary bladder cancer	2.51e-05	0.000122	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	2.5e-05	0.000122	CcSEcCtD
Bortezomib—Insomnia—Doxorubicin—urinary bladder cancer	2.48e-05	0.000121	CcSEcCtD
Bortezomib—Paraesthesia—Doxorubicin—urinary bladder cancer	2.47e-05	0.00012	CcSEcCtD
Bortezomib—Dyspnoea—Doxorubicin—urinary bladder cancer	2.45e-05	0.000119	CcSEcCtD
Bortezomib—Feeling abnormal—Epirubicin—urinary bladder cancer	2.45e-05	0.000119	CcSEcCtD
Bortezomib—Gastrointestinal pain—Epirubicin—urinary bladder cancer	2.43e-05	0.000118	CcSEcCtD
Bortezomib—Dyspepsia—Doxorubicin—urinary bladder cancer	2.42e-05	0.000117	CcSEcCtD
Bortezomib—Decreased appetite—Doxorubicin—urinary bladder cancer	2.39e-05	0.000116	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	2.37e-05	0.000115	CcSEcCtD
Bortezomib—Fatigue—Doxorubicin—urinary bladder cancer	2.37e-05	0.000115	CcSEcCtD
Bortezomib—Urticaria—Epirubicin—urinary bladder cancer	2.36e-05	0.000115	CcSEcCtD
Bortezomib—Constipation—Doxorubicin—urinary bladder cancer	2.35e-05	0.000114	CcSEcCtD
Bortezomib—Pain—Doxorubicin—urinary bladder cancer	2.35e-05	0.000114	CcSEcCtD
Bortezomib—Body temperature increased—Epirubicin—urinary bladder cancer	2.35e-05	0.000114	CcSEcCtD
Bortezomib—Abdominal pain—Epirubicin—urinary bladder cancer	2.35e-05	0.000114	CcSEcCtD
Bortezomib—Hypersensitivity—Methotrexate—urinary bladder cancer	2.34e-05	0.000113	CcSEcCtD
Bortezomib—Asthenia—Methotrexate—urinary bladder cancer	2.27e-05	0.000111	CcSEcCtD
Bortezomib—Feeling abnormal—Doxorubicin—urinary bladder cancer	2.26e-05	0.00011	CcSEcCtD
Bortezomib—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	2.25e-05	0.000109	CcSEcCtD
Bortezomib—Pruritus—Methotrexate—urinary bladder cancer	2.24e-05	0.000109	CcSEcCtD
Bortezomib—Hypersensitivity—Epirubicin—urinary bladder cancer	2.19e-05	0.000106	CcSEcCtD
Bortezomib—Urticaria—Doxorubicin—urinary bladder cancer	2.18e-05	0.000106	CcSEcCtD
Bortezomib—Body temperature increased—Doxorubicin—urinary bladder cancer	2.17e-05	0.000105	CcSEcCtD
Bortezomib—Abdominal pain—Doxorubicin—urinary bladder cancer	2.17e-05	0.000105	CcSEcCtD
Bortezomib—Diarrhoea—Methotrexate—urinary bladder cancer	2.17e-05	0.000105	CcSEcCtD
Bortezomib—Asthenia—Epirubicin—urinary bladder cancer	2.13e-05	0.000103	CcSEcCtD
Bortezomib—Pruritus—Epirubicin—urinary bladder cancer	2.1e-05	0.000102	CcSEcCtD
Bortezomib—Dizziness—Methotrexate—urinary bladder cancer	2.1e-05	0.000102	CcSEcCtD
Bortezomib—Diarrhoea—Epirubicin—urinary bladder cancer	2.03e-05	9.86e-05	CcSEcCtD
Bortezomib—Hypersensitivity—Doxorubicin—urinary bladder cancer	2.02e-05	9.83e-05	CcSEcCtD
Bortezomib—Vomiting—Methotrexate—urinary bladder cancer	2.02e-05	9.79e-05	CcSEcCtD
Bortezomib—Rash—Methotrexate—urinary bladder cancer	2e-05	9.71e-05	CcSEcCtD
Bortezomib—Dermatitis—Methotrexate—urinary bladder cancer	2e-05	9.7e-05	CcSEcCtD
Bortezomib—Headache—Methotrexate—urinary bladder cancer	1.99e-05	9.65e-05	CcSEcCtD
Bortezomib—Asthenia—Doxorubicin—urinary bladder cancer	1.97e-05	9.57e-05	CcSEcCtD
Bortezomib—Dizziness—Epirubicin—urinary bladder cancer	1.96e-05	9.53e-05	CcSEcCtD
Bortezomib—Pruritus—Doxorubicin—urinary bladder cancer	1.94e-05	9.44e-05	CcSEcCtD
Bortezomib—Vomiting—Epirubicin—urinary bladder cancer	1.89e-05	9.17e-05	CcSEcCtD
Bortezomib—Nausea—Methotrexate—urinary bladder cancer	1.88e-05	9.15e-05	CcSEcCtD
Bortezomib—Diarrhoea—Doxorubicin—urinary bladder cancer	1.88e-05	9.13e-05	CcSEcCtD
Bortezomib—Rash—Epirubicin—urinary bladder cancer	1.87e-05	9.09e-05	CcSEcCtD
Bortezomib—Dermatitis—Epirubicin—urinary bladder cancer	1.87e-05	9.08e-05	CcSEcCtD
Bortezomib—Headache—Epirubicin—urinary bladder cancer	1.86e-05	9.03e-05	CcSEcCtD
Bortezomib—Dizziness—Doxorubicin—urinary bladder cancer	1.82e-05	8.82e-05	CcSEcCtD
Bortezomib—Nausea—Epirubicin—urinary bladder cancer	1.76e-05	8.56e-05	CcSEcCtD
Bortezomib—Vomiting—Doxorubicin—urinary bladder cancer	1.75e-05	8.48e-05	CcSEcCtD
Bortezomib—Rash—Doxorubicin—urinary bladder cancer	1.73e-05	8.41e-05	CcSEcCtD
Bortezomib—Dermatitis—Doxorubicin—urinary bladder cancer	1.73e-05	8.4e-05	CcSEcCtD
Bortezomib—Headache—Doxorubicin—urinary bladder cancer	1.72e-05	8.36e-05	CcSEcCtD
Bortezomib—Nausea—Doxorubicin—urinary bladder cancer	1.63e-05	7.92e-05	CcSEcCtD
Bortezomib—PSMD1—Disease—HRAS—urinary bladder cancer	5.7e-06	3.3e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—SRC—urinary bladder cancer	5.7e-06	3.3e-05	CbGpPWpGaD
Bortezomib—PSMD2—Disease—HRAS—urinary bladder cancer	5.67e-06	3.29e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—SRC—urinary bladder cancer	5.67e-06	3.29e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—GPX1—urinary bladder cancer	5.67e-06	3.29e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—SRC—urinary bladder cancer	5.64e-06	3.27e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—PTEN—urinary bladder cancer	5.57e-06	3.23e-05	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—PTEN—urinary bladder cancer	5.57e-06	3.23e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—PTEN—urinary bladder cancer	5.57e-06	3.23e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—ERCC2—urinary bladder cancer	5.57e-06	3.23e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—KRAS—urinary bladder cancer	5.53e-06	3.21e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—KRAS—urinary bladder cancer	5.53e-06	3.21e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—KRAS—urinary bladder cancer	5.53e-06	3.21e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ENO2—urinary bladder cancer	5.53e-06	3.2e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	5.53e-06	3.2e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—MYC—urinary bladder cancer	5.53e-06	3.2e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—MYC—urinary bladder cancer	5.53e-06	3.2e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—MYC—urinary bladder cancer	5.53e-06	3.2e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	5.49e-06	3.19e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—PTEN—urinary bladder cancer	5.49e-06	3.18e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—RRM2—urinary bladder cancer	5.49e-06	3.18e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—ERBB2—urinary bladder cancer	5.46e-06	3.17e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—ERBB2—urinary bladder cancer	5.46e-06	3.17e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—ERBB2—urinary bladder cancer	5.46e-06	3.17e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—KRAS—urinary bladder cancer	5.45e-06	3.16e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—MYC—urinary bladder cancer	5.45e-06	3.16e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—NQO1—urinary bladder cancer	5.44e-06	3.16e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—RRM2—urinary bladder cancer	5.44e-06	3.15e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—EGFR—urinary bladder cancer	5.41e-06	3.13e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—EGFR—urinary bladder cancer	5.41e-06	3.13e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—EGFR—urinary bladder cancer	5.41e-06	3.13e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—NAT2—urinary bladder cancer	5.39e-06	3.12e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—ERBB2—urinary bladder cancer	5.38e-06	3.12e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	5.36e-06	3.11e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—EGFR—urinary bladder cancer	5.33e-06	3.09e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—EP300—urinary bladder cancer	5.31e-06	3.08e-05	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—EP300—urinary bladder cancer	5.31e-06	3.08e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—EP300—urinary bladder cancer	5.31e-06	3.08e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	5.28e-06	3.06e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	5.28e-06	3.06e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—EP300—urinary bladder cancer	5.24e-06	3.04e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—MTHFR—urinary bladder cancer	5.23e-06	3.03e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CXCL8—urinary bladder cancer	5.18e-06	3e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CXCL8—urinary bladder cancer	5.18e-06	3e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CXCL8—urinary bladder cancer	5.18e-06	3e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—MYC—urinary bladder cancer	5.11e-06	2.96e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—KRAS—urinary bladder cancer	5.11e-06	2.96e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—KRAS—urinary bladder cancer	5.11e-06	2.96e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—KRAS—urinary bladder cancer	5.11e-06	2.96e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CXCL8—urinary bladder cancer	5.11e-06	2.96e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	5.08e-06	2.95e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ENO2—urinary bladder cancer	5.08e-06	2.95e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—MYC—urinary bladder cancer	5.08e-06	2.95e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—MYC—urinary bladder cancer	5.06e-06	2.93e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	5.04e-06	2.92e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ENO2—urinary bladder cancer	5.04e-06	2.92e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—KRAS—urinary bladder cancer	5.03e-06	2.92e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	5.01e-06	2.9e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—EGFR—urinary bladder cancer	4.99e-06	2.9e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—NQO1—urinary bladder cancer	4.99e-06	2.89e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—EGFR—urinary bladder cancer	4.97e-06	2.88e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—IL2—urinary bladder cancer	4.95e-06	2.87e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—IL2—urinary bladder cancer	4.95e-06	2.87e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—IL2—urinary bladder cancer	4.95e-06	2.87e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—EGFR—urinary bladder cancer	4.95e-06	2.87e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	4.93e-06	2.86e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	4.89e-06	2.83e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—IL2—urinary bladder cancer	4.88e-06	2.83e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.84e-06	2.81e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CCND1—urinary bladder cancer	4.82e-06	2.8e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CCND1—urinary bladder cancer	4.82e-06	2.8e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CCND1—urinary bladder cancer	4.82e-06	2.8e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.81e-06	2.79e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CCND1—urinary bladder cancer	4.76e-06	2.76e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—KRAS—urinary bladder cancer	4.72e-06	2.74e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—HRAS—urinary bladder cancer	4.7e-06	2.73e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—HRAS—urinary bladder cancer	4.7e-06	2.73e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—HRAS—urinary bladder cancer	4.7e-06	2.73e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—KRAS—urinary bladder cancer	4.7e-06	2.72e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MMP9—urinary bladder cancer	4.68e-06	2.72e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MMP9—urinary bladder cancer	4.68e-06	2.72e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MMP9—urinary bladder cancer	4.68e-06	2.72e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—KRAS—urinary bladder cancer	4.67e-06	2.71e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CDKN1A—urinary bladder cancer	4.67e-06	2.71e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CDKN1A—urinary bladder cancer	4.67e-06	2.71e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CDKN1A—urinary bladder cancer	4.67e-06	2.71e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—PTEN—urinary bladder cancer	4.66e-06	2.7e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—PTEN—urinary bladder cancer	4.66e-06	2.7e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—PTEN—urinary bladder cancer	4.66e-06	2.7e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—RRM2—urinary bladder cancer	4.65e-06	2.7e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—HRAS—urinary bladder cancer	4.63e-06	2.69e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MMP9—urinary bladder cancer	4.62e-06	2.68e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	4.61e-06	2.67e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CDKN1A—urinary bladder cancer	4.6e-06	2.67e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—TYMP—urinary bladder cancer	4.6e-06	2.66e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—PTEN—urinary bladder cancer	4.59e-06	2.66e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—GSTP1—urinary bladder cancer	4.54e-06	2.63e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—NQO1—urinary bladder cancer	4.45e-06	2.58e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—EP300—urinary bladder cancer	4.44e-06	2.57e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—EP300—urinary bladder cancer	4.44e-06	2.57e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—EP300—urinary bladder cancer	4.44e-06	2.57e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	4.39e-06	2.55e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—EP300—urinary bladder cancer	4.38e-06	2.54e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—HRAS—urinary bladder cancer	4.34e-06	2.52e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—HRAS—urinary bladder cancer	4.34e-06	2.52e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—HRAS—urinary bladder cancer	4.34e-06	2.52e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.32e-06	2.51e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—SRC—urinary bladder cancer	4.32e-06	2.5e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—SRC—urinary bladder cancer	4.32e-06	2.5e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—SRC—urinary bladder cancer	4.32e-06	2.5e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	4.31e-06	2.5e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ENO2—urinary bladder cancer	4.31e-06	2.5e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.28e-06	2.48e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—HRAS—urinary bladder cancer	4.28e-06	2.48e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—SRC—urinary bladder cancer	4.26e-06	2.47e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PPARG—urinary bladder cancer	4.24e-06	2.46e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	4.22e-06	2.45e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—TYMS—urinary bladder cancer	4.22e-06	2.45e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TP53—urinary bladder cancer	4.19e-06	2.43e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	4.18e-06	2.42e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TP53—urinary bladder cancer	4.17e-06	2.42e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—GSTM1—urinary bladder cancer	4.17e-06	2.42e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—NCOR1—urinary bladder cancer	4.17e-06	2.42e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	4.16e-06	2.41e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—NAT2—urinary bladder cancer	4.16e-06	2.41e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TP53—urinary bladder cancer	4.15e-06	2.41e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.11e-06	2.38e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—NQO1—urinary bladder cancer	4.1e-06	2.38e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—CREBBP—urinary bladder cancer	4.08e-06	2.36e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—NQO1—urinary bladder cancer	4.06e-06	2.35e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	4.03e-06	2.33e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—HRAS—urinary bladder cancer	4.01e-06	2.33e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—GPX1—urinary bladder cancer	4e-06	2.32e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—HRAS—urinary bladder cancer	3.99e-06	2.31e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—HRAS—urinary bladder cancer	3.97e-06	2.3e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.94e-06	2.28e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—ERCC2—urinary bladder cancer	3.92e-06	2.27e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MYC—urinary bladder cancer	3.87e-06	2.24e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MYC—urinary bladder cancer	3.87e-06	2.24e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MYC—urinary bladder cancer	3.87e-06	2.24e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—TYMS—urinary bladder cancer	3.87e-06	2.24e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	3.83e-06	2.22e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	3.83e-06	2.22e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MYC—urinary bladder cancer	3.82e-06	2.21e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—EGFR—urinary bladder cancer	3.79e-06	2.19e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—EGFR—urinary bladder cancer	3.79e-06	2.19e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—EGFR—urinary bladder cancer	3.79e-06	2.19e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.77e-06	2.19e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—EGFR—urinary bladder cancer	3.73e-06	2.16e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	3.72e-06	2.15e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—MTHFR—urinary bladder cancer	3.69e-06	2.14e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GPX1—urinary bladder cancer	3.66e-06	2.12e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	3.6e-06	2.09e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.59e-06	2.08e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—RRM2—urinary bladder cancer	3.59e-06	2.08e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—KRAS—urinary bladder cancer	3.58e-06	2.07e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—KRAS—urinary bladder cancer	3.58e-06	2.07e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—KRAS—urinary bladder cancer	3.58e-06	2.07e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—KRAS—urinary bladder cancer	3.53e-06	2.04e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—NQO1—urinary bladder cancer	3.47e-06	2.01e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—TYMS—urinary bladder cancer	3.45e-06	2e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.44e-06	1.99e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	3.42e-06	1.98e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	3.41e-06	1.98e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	3.41e-06	1.98e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	3.39e-06	1.96e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	3.38e-06	1.96e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.37e-06	1.95e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PTGS2—urinary bladder cancer	3.34e-06	1.94e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	3.32e-06	1.93e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ENO2—urinary bladder cancer	3.32e-06	1.93e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.28e-06	1.9e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GPX1—urinary bladder cancer	3.27e-06	1.9e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	3.22e-06	1.87e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	3.21e-06	1.86e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TP53—urinary bladder cancer	3.18e-06	1.84e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TP53—urinary bladder cancer	3.18e-06	1.84e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TP53—urinary bladder cancer	3.18e-06	1.84e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—TYMS—urinary bladder cancer	3.18e-06	1.84e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—TYMS—urinary bladder cancer	3.15e-06	1.83e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	3.14e-06	1.82e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	3.14e-06	1.82e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TP53—urinary bladder cancer	3.13e-06	1.82e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	3.11e-06	1.8e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	3.11e-06	1.8e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—HRAS—urinary bladder cancer	3.04e-06	1.76e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—HRAS—urinary bladder cancer	3.04e-06	1.76e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—HRAS—urinary bladder cancer	3.04e-06	1.76e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	3.02e-06	1.75e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GPX1—urinary bladder cancer	3.01e-06	1.74e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—HRAS—urinary bladder cancer	3e-06	1.74e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PPARG—urinary bladder cancer	2.99e-06	1.73e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GPX1—urinary bladder cancer	2.98e-06	1.73e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	2.95e-06	1.71e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.94e-06	1.7e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	2.93e-06	1.7e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PTEN—urinary bladder cancer	2.91e-06	1.69e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	2.89e-06	1.68e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—CREBBP—urinary bladder cancer	2.87e-06	1.67e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.8e-06	1.62e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—EP300—urinary bladder cancer	2.78e-06	1.61e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	2.78e-06	1.61e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	2.75e-06	1.6e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PPARG—urinary bladder cancer	2.74e-06	1.59e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—TYMS—urinary bladder cancer	2.69e-06	1.56e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—NQO1—urinary bladder cancer	2.68e-06	1.55e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	2.66e-06	1.54e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	2.66e-06	1.54e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	2.63e-06	1.53e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GPX1—urinary bladder cancer	2.55e-06	1.48e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	2.5e-06	1.45e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PPARG—urinary bladder cancer	2.45e-06	1.42e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PTGS2—urinary bladder cancer	2.35e-06	1.36e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	2.35e-06	1.36e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	2.35e-06	1.36e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PPARG—urinary bladder cancer	2.25e-06	1.3e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	2.23e-06	1.3e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PPARG—urinary bladder cancer	2.23e-06	1.29e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	2.16e-06	1.25e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	2.16e-06	1.25e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	2.14e-06	1.24e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—TYMS—urinary bladder cancer	2.08e-06	1.2e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	2.05e-06	1.19e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	2.05e-06	1.19e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PTEN—urinary bladder cancer	2.05e-06	1.19e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.97e-06	1.14e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—EP300—urinary bladder cancer	1.96e-06	1.13e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.93e-06	1.12e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	1.92e-06	1.12e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PPARG—urinary bladder cancer	1.91e-06	1.11e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PTEN—urinary bladder cancer	1.88e-06	1.09e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	1.83e-06	1.06e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.81e-06	1.05e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—EP300—urinary bladder cancer	1.79e-06	1.04e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	1.77e-06	1.03e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	1.76e-06	1.02e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PTEN—urinary bladder cancer	1.68e-06	9.73e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—EP300—urinary bladder cancer	1.6e-06	9.28e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PTEN—urinary bladder cancer	1.54e-06	8.95e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PTEN—urinary bladder cancer	1.53e-06	8.87e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	1.5e-06	8.7e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—EP300—urinary bladder cancer	1.47e-06	8.54e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PPARG—urinary bladder cancer	1.47e-06	8.53e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—EP300—urinary bladder cancer	1.46e-06	8.46e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	1.41e-06	8.19e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PTEN—urinary bladder cancer	1.31e-06	7.58e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—EP300—urinary bladder cancer	1.25e-06	7.23e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	1.16e-06	6.71e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PTEN—urinary bladder cancer	1.01e-06	5.85e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—EP300—urinary bladder cancer	9.63e-07	5.58e-06	CbGpPWpGaD
